Investment Announcement - General Motors is investing $888 million in its Tonawanda Propulsion plant in Buffalo, New York, to support the production of the sixth generation of GM's V-8 engines [1][5] - This investment marks a shift from a previously announced $300 million commitment for electric-vehicle drive units at the same plant [1][5] Engine Development - The new V-8 engines are expected to provide better fuel economy and reduce emissions through new combustion and thermal management innovations [2] - The plant will continue producing fifth generation V-8 engines while preparing for the sixth generation, which is set to start production in 2027 [5] Job Creation and Economic Impact - The project will support 870 jobs at the Tonawanda Propulsion plant, including 177 jobs that were deemed at risk [6] - New York State plans to provide up to $16.96 million in tax credits in exchange for GM's investment commitments [6] Commitment to Manufacturing - GM's investment reflects a commitment to strengthening American manufacturing and supporting jobs in the U.S. [2] - The Buffalo plant has been operational for 87 years and continues to innovate in engine production to enhance fuel efficiency and performance [3]

Core Points - Argenx SE held its Annual General Meeting on May 27, 2025, with 91.1% of the share capital represented [1] - All agenda items received the required majority except for the remuneration policy, which received a 73.0% majority against a required 75% [2] - The company's 2024 remuneration report received a 76.7% majority in favor [4] - The annual report and accounts for the financial year ending December 31, 2024, were approved with a 99.9% majority [4] - Anthony Rosenberg was re-appointed as a non-executive director for a two-year term with a 93.6% majority [4] - The Board of Directors was authorized to issue shares and grant rights to subscribe for shares for up to 10% of the outstanding share capital for 18 months, with a 99.4% majority [4] Company Overview - Argenx is a global immunology company focused on improving the lives of individuals with severe autoimmune diseases [3] - The company collaborates with leading academic researchers through its Immunology Innovation Program to develop novel antibody-based medicines [3] - Argenx has developed the first approved neonatal Fc receptor (FcRn) blocker and is exploring its potential in various serious autoimmune diseases [3]

As I mentioned in more detail in a previous write-up , I like to classify my investments into different buckets. Regarding Dollar General (NYSE: DG ), I put them in my medium-term bucket but believe they could end upI am a CFA Charterholder, have my M.B.A. from a Top 20 Business school, and am a Marine Corps Veteran. My investment approach is opportunistic, flexible, fundamentally based, and valuation driven. I will invest in individual stocks, options, warrants, bonds, ETF's, CEF's, or mutual funds based o ...

Group 1 - General Motors is investing $888 million in its Tonawanda Propulsion plant to support the production of the sixth generation of V-8 engines, shifting from a previous $300 million commitment for electric-vehicle drive units [1][2] - The new V-8 engines are expected to provide better fuel economy and reduce emissions through new combustion and thermal management innovations [2] - The investment will support 870 jobs at the Tonawanda Propulsion plant, including 177 jobs deemed at risk, with New York State providing up to $16.96 million in tax credits [8] Group 2 - The Tonawanda Propulsion plant has been operational for 87 years and will continue producing fifth generation V-8 engines while preparing for the sixth generation production set to start in 2027 [5] - The move reflects automakers adapting to slower-than-expected market demand for electric vehicles and follows GM's lobbying efforts against California's electric-vehicle regulations [8]

Core Viewpoint - Dollar General has seen a significant stock price increase of 33% this year, outperforming the S&P 500 index, which gained only 0.5% [1] Financial Performance - The company will report its latest earnings on June 3, which is expected to cause rapid stock movement [2] - Despite the current stock performance, Dollar General's stock is down over 44% from its mid-2020 price, indicating a volatile five-year performance [4] - For the current fiscal year, Dollar General projects net sales growth between 3.4% and 4.4%, but same-store sales growth is only expected to be between 1.2% and 2.2% [10] Business Model and Market Position - Dollar General focuses on domestically produced essential goods, with only about 4% of its inventory sourced from imports, making it less vulnerable to tariff-related price increases [6] - The company plans to open 575 new stores in the U.S. during the current fiscal year, which is a significant factor behind its projected top-line growth [10] Investment Considerations - The stock is currently trading around $101, significantly lower than its early 2023 price of just below $240, suggesting potential for further rally if recent performance is solid [7] - Despite the stock's recent success, there are concerns about the company's financial health, as many customers report only having enough money for basic essentials, indicating limited organic growth [10] - The stock's valuation is approaching its five-year average, leading to caution regarding future performance and potential risks associated with the core customer base in rural areas [11][12]

Group 1: Contract Award - General Dynamics Corp.'s NASSCO unit secured a $199 million contract for the maintenance, modernization, and repair of the USS America (LHA 6) warship, with potential total value reaching $209.2 million if options are exercised [1] - The contract is expected to be completed by July 2027, with work to be conducted in San Diego, CA [1] Group 2: Market Trends - Rising geopolitical tensions are increasing global investment in advanced naval vessels, benefiting shipbuilders like General Dynamics [2] - The demand for efficient naval security systems is driving growth in the naval ship market, with a projected compound annual growth rate of 6.5% for the global naval combat vessels market from 2025 to 2030 [4] Group 3: Company Positioning - General Dynamics' Marine Systems segment specializes in designing and building surface combatant and auxiliary ships for the U.S. Navy, along with modernization and lifecycle extension services [5] - The company's marine engineering expertise positions it well to secure more contracts, enhancing future revenue prospects [5] Group 4: Peer Opportunities - Lockheed Martin manufactures Littoral Combat Ships (LCS) with a long-term earnings growth rate of 10.5% and a projected 4.6% sales improvement in 2025 [6][7] - Huntington Ingalls Industries designs and constructs non-nuclear ships for the U.S. Navy and Coast Guard, with a long-term earnings growth rate of 11% and a 3.3% sales increase projected for 2025 [7][8] - BAE Systems designs and supports a range of naval ships, boasting a long-term earnings growth rate of 11.9% and a significant 62.6% sales growth estimate for 2025 [8][9] Group 5: Price Performance - General Dynamics shares have increased by 8.8% over the past three months, outperforming the industry growth of 8% [12]

Company Overview - Cardiol Therapeutics Inc. is a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease [4] - The company's lead drug candidate, CardiolRx™ (cannabidiol) oral solution, is in clinical development for treating heart disease and is recognized for inhibiting the inflammasome pathway, which is crucial in inflammation and fibrosis related to myocarditis, pericarditis, and heart failure [4] Clinical Development - Cardiol has received Investigational New Drug Application authorization from the US FDA to conduct clinical studies for CardiolRx™ in recurrent pericarditis and acute myocarditis [5] - The MAVERIC Program for recurrent pericarditis includes the completed Phase II MAvERIC-Pilot study and the ongoing Phase III MAVERIC trial [5] - The ongoing ARCHER trial is a Phase II study in acute myocarditis, a significant cause of heart failure and sudden cardiac death in young adults [5] Financial Context - Heart failure is a leading cause of death and hospitalization in developed countries, with associated healthcare costs in the US exceeding $30 billion annually [6] Upcoming Events - The company's virtual Annual General Meeting (AGM) is scheduled for May 28, 2025, at 4:30 p.m. EDT, and will be accessible via live audio webcast [2][3]

Core Viewpoint - BofA Securities analyst Robert F. Ohmes maintains a Buy rating on Dollar General Corp, increasing the price target from $100 to $115, anticipating positive financial results for the fiscal 2025 first quarter [1]. Financial Performance - Dollar General is expected to report an adjusted EPS of $1.40 for Q1, with comparable sales projected to rise by 1% [1]. - Real-time sales data indicates an acceleration in sales for the quarter, suggesting potential upside compared to current estimates [2]. Operational Insights - Profit gains from reduced shrink are expected to be offset by pressures from store remodel activities and labor costs, with approximately $20 million in expenses related to store closures [3]. - Margin performance is anticipated to improve progressively throughout the year [3]. Strategic Initiatives - The company is expected to benefit from trade-in programs that will support comparable sales and mitigate spending fluctuations among core customers, with adoption gaining traction [4]. - Despite concerns over Walmart's stronger comp performance, Dollar General's significant price gaps, digital expansion momentum, and ongoing store closures at competitors are seen as supportive factors [5]. Market Activity - Dollar General shares are currently trading higher by 1.25% at $101.90 [6].

Parkev Tatevosian, CFA has no position in any of the stocks mentioned. The Motley Fool recommends General Motors. The Motley Fool has a disclosure policy. Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool. ...

Group 1 - Constellium SE held its Annual General Meeting of Shareholders on May 15, 2025, and published the voting results on its website [1] - All proposals at the AGM were adopted, including the appointment of Bradley Soultz and the re-appointment of Emmanuel Blot, Martha Brooks, and Lori Walker to the Board of Directors for a three-year term [2] - Constellium is a global leader in developing innovative, value-added aluminum products for various markets, generating $7.3 billion in revenue in 2024 [3]